Point-of-care coagulation testing market seen reaching $1.52B by 2030

The point-of-care coagulation testing market reached $1.25 billion in 2025 and is projected to hit $1.52 billion by 2030, driven by faster bedside diagnostics and rising cardiovascular disease cases. North America held the largest regional share in 2025, while demand is expected to expand as care shifts toward decentralized and home-based testing.

Why it matters: - Point-of-care coagulation tests give clinicians blood-clotting results in minutes instead of relying on centralized labs. - Faster results can speed treatment decisions in surgery, intensive care, emergency care and trauma care. - The market is growing alongside the rising burden of cardiovascular disease, where anticoagulation management often depends on quick coagulation monitoring.

What happened: - The Business Research Company projected the global point-of-care coagulation testing market will reach $1.52 billion by 2030. - The market was valued at $1.25 billion in 2025 and is expected to rise to $1.3 billion in 2026. - The report estimated a 4.2% compound annual growth rate from 2025 to 2026 and a 4.1% CAGR through 2030. - North America held the largest share of the global market in 2025. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.

The details: - Historical growth has been driven by more cardiovascular disease cases requiring anticoagulation therapy. - Demand has also increased for quick coagulation results in surgical and intensive care settings. - Early adoption of optical and mechanical testing technologies has supported market expansion. - Hospitals and clinics have widened use of coagulation monitoring. - Future growth is expected to come from decentralized and home-based testing, wider use of electrochemical detection, and more emergency and trauma procedures. - Retail and direct tender channels are also expected to support adoption. - The report points to a push to reduce turnaround times and improve therapy outcomes. - Forecast trends include more rapid bedside tests in critical care, greater use of portable and handheld devices, expansion in home care and outpatient settings, and more real-time clinical decision support through near-patient diagnostics. - The report describes point-of-care coagulation testing as diagnostics performed at or near the patient rather than in a centralized lab. - The tests can deliver results in real time or within minutes. - That speed helps clinicians manage anticoagulation therapy and improve patient outcomes. - The report said cardiovascular diseases caused about 919,032 deaths in the U.S. in 2023, according to CDC data cited in October 2024. - Those deaths represented one in every three U.S. deaths, and about one-sixth occurred in adults under 65.

Between the lines: - The market story is not just about device sales. It is about moving clotting diagnostics closer to the bedside and away from slower lab workflows. - The strongest demand signal comes from care settings where minutes matter and treatment decisions can affect bleeding risk and procedure outcomes. - North America’s lead suggests the region already has broad access to these tests, while other regions may have more room to expand as decentralized care models spread.

What's next: - The market is expected to keep growing steadily through 2030 rather than accelerate sharply. - Adoption should rise in home care, outpatient care and portable testing formats. - More access through retail and direct tender channels could widen use beyond traditional hospital settings. - The Business Research Company also promoted updated 2026 report features, including market attractiveness scoring, TAM analysis, company scoring matrices, Excel forecasting dashboards, hotspot infographics and updated graphics and tables. - The company provided sample and full-report links for the market study, including a free sample and the full report.

The bottom line: - Point-of-care coagulation testing is shifting from a niche hospital tool to a broader near-patient diagnostics market, with cardiovascular care as the main growth engine.